CNTX - Latest News
Context Therapeutics Inc. (CNTX), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $273.8M. Beta to the broader market is 1.57.
The article list below shows the most recent CNTX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent CNTX Headlines
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
globenewswire.com - May 27, 2026
PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceuti
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
globenewswire.com - May 18, 2026
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
globenewswire.com - May 6, 2026
Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expecte
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
globenewswire.com - Apr 2, 2026
Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
defenseworld.net - Mar 28, 2026
Context Therapeutics Inc. (NASDAQ: CNTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine research firms tha
How News Affects CNTX Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track CNTX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked CNTX news questions
- What is the latest CNTX news headline?
- The most recent CNTX headline (May 27, 2026) is "Context Therapeutics to Present at the Jefferies Global Healthcare Conference". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the CNTX news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What CNTX news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual CNTX options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.